RxDoctor Payments Data

Jose Pavia, MD

Family Medicine · Chino, CANPI 1447251145

Payments from drug & device makers

$980in general payments, 2019–2025

Across 45 payments — averaging $21.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$441
  • Novo Nordisk$124
  • Pfizer$108
  • GSK$74
  • Johnson & Johnson$65
  • Amgen$63
  • plus $105 from 4 others

What the payments were for

  • Food & beverage$980100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca18$441
Novo Nordisk6$124
Pfizer5$108
GSK4$74
Johnson & Johnson4$65
Amgen3$63
Lilly USA, LLC2$42
Merck1$23
Exact Sciences1$20
Bayer1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$980 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$28,560
Medicare patients
105
Services billed
372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$73,872
OzempicSemaglutide52$46,123
JardianceEmpagliflozin26$30,646
TrulicityDulaglutide23$21,641
JanuviaSitagliptin Phosphate14$20,109
MyrbetriqMirabegron11$14,772
Cyclosporine15$9,014
Atorvastatin Calcium409$4,467
Colchicine20$3,563
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,303
Dabigatran EtexilateDabigatran Etexilate Mesylate14$2,702
Losartan Potassium201$2,428
Wixela InhubFluticasone Propion/Salmeterol12$2,247
Ezetimibe69$2,169
Metformin Hcl243$2,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$108$73,87266 claims
Novo NordiskOzempic$124$46,12352 claims
Lilly USA, LLCTrulicity$42$21,64123 claims
MerckJanuvia$23$20,10914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Chino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →